Targeting RANKL for reduction of bone loss around unstable implants: OPG-Fc compared to alendronate in a model for mechanically induced loosening

Bone

Volumn 48, Issue 2, 2011, Pages 225-230

  Aspenberg, Per ^a   Agholme, Fredrik ^a   Magnusson, Per ^a   Fahlgren, Anna ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Bisphosphonates; Implant; Instability; Loosening; RANKL; Resorption

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE RECEPTOR ANTAGONIST; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN FC; SODIUM CHLORIDE; TITANIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE REGENERATION; BONE REMODELING; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TARGETING; FLUID FLOW; HYDROSTATIC PRESSURE; IMPLANT; MALE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROSTHESIS LOOSENING; RANDOMIZATION; RAT; TIBIA;

ACID PHOSPHATASE; ALENDRONATE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE PLATES; BONE RESORPTION; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; OSTEOPROTEGERIN; PROSTHESES AND IMPLANTS; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; TIBIA;

EID: 78650981373     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.09.024     Document Type: Article

References (22)

1. Shanbhag A.S., Hasselman C.T., Rubash H.E. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop Relat Res 1997, 33-43.
2. Astrand J., Aspenberg P. Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats. Acta Orthop Scand 2002, 73:24-30.
3. Rubash H.E., Dorr L., Jacobs J., Maloney W., Saag K., Malbecq W., et al. Does alendronate inhibit the progression of periprosthetic osteolysis?. Tran Orthop Res Soc 2004, 29:1888.
4. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
5. Bradaschia-Correa V., Massa L.F., Arana-Chavez V.E. Effects of alendronate on tooth eruption and molar root formation in young growing rats. Cell Tissue Res 2007, 330:475-485.
6. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
7. Kostenuik P.J., Nguyen H.Q., McCabe J., Warmington K.S., Kurahara C., Sun N., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009, 24:182-195.
8. Aspenberg P., Van der Vis H. Migration, particles, and fluid pressure. A discussion of causes of prosthetic loosening. Clin Orthop Relat Res 1998, 75-80.
9. Perren S.M. Evolution of the internal fixation of long bone fractures. The scientific basis of biological internal fixation: choosing a new balance between stability and biology. J Bone Joint Surg Br 2002, 84:1093-1110.
10. Fahlgren A., Bostrom M.P.G., Yang X., Johansson L., Edlund U., Agholme F., Aspenberg P. Fluid pressure and flow as a cause of bone resorption. Acta Orthop 2010, 81:508-516.
11. Astrand J., Skripitz R., Skoglund B., Aspenberg P. A rat model for testing pharmacologic treatments of pressure-related bone loss. Clin Orthop Relat Res 2003, 296-305.
12. Zenger S., Hollberg K., Ljusberg J., Norgard M., Ek-Rylander B., Kiviranta R., et al. Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice. Bone 2007, 41:820-832.
13. Alatalo S.L., Peng Z., Janckila A.J., Kaija H., Vihko P., Vaananen H.K., et al. A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum. J Bone Miner Res 2003, 18:134-139.
14. Yang Li C., Majeska R.J., Laudier D.M., Mann R., Schaffler M.B. High-dose risedronate treatment partially preserves cancellous bone mass and microarchitecture during long-term disuse. Bone 2005, 37:287-295.
15. Lewiecki E.M., Miller P.D., McClung M.R., Cohen S.B., Bolognese M.A., Liu Y., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007, 22:1832-1841.
16. Capparelli C., Morony S., Warmington K., Adamu S., Lacey D., Dunstan C.R., et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 2003, 18:852-858.
17. Ominsky M.S., Li X., Asuncion F.J., Barrero M., Warmington K.S., Dwyer D., et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res 2008, 23:672-682.
18. Fender D., van der Meulen J.H., Gregg P.J. Relationship between outcome and annual surgical experience for the charnley total hip replacement. Results from a regional hip register. J Bone Joint Surg Br 2003, 85:187-190.
19. Ryd L., Albrektsson B.E., Carlsson L., Dansgard F., Herberts P., Lindstrand A., et al. Roentgen stereophotogrammetric analysis as a predictor of mechanical loosening of knee prostheses. J Bone Joint Surg Br 1995, 77:377-383.
20. Weinstein R.S., Roberson P.K., Manolagas S.C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009, 360:53-62.
21. Goodman S., Aspenberg P., Song Y., Regula D., Lidgren L. Polyethylene and titanium alloy particles reduce bone formation. Dose-dependence in bone harvest chamber experiments in rabbits. Acta Orthop Scand 1996, 67:599-605.
22. Hilding M., Aspenberg P. Postoperative clodronate decreases prosthetic migration: 4-year follow-up of a randomized radiostereometric study of 50 total knee patients. Acta Orthop 2006, 77:912-916.